The supernatants from the mDC-naive T co-cultures of cells from RR-MS patients, regardless of treatment status, did not demonstrate the upregulation of IL10 and downregulation of the proinflammatory cytokines IL-17F, TNF-α, and IL-23, as well as the lymphocyte activation marker 4-1BB (CD137), observed in the healthy donor mDC co-cultures. This evidence concerns the gene IL17F and myeloid sarcoma.